May Guo About mRNA Based in Vivo MG1113 Antibody Production as a Potential Therapeutic Approach for Hemophilia
May Guo, Vice President of Business Development at Biomay AG and Founder and CEO of Novaribo Consulting, shared a post on her LinkedIn account:
“mRNA/LNP encoding MG1113, a humanized monoclonal antibody that targets tissue factor pathway inhibitor (TFPI), to treat hemophilia. This paper shows that a single IV dose of mRNA-LNP achieves substantially higher peak serum concentrations of MG1113 antibody compared with direct antibody administration, demonstrating the pharmacokinetic advantage of mRNA-encoded antibody delivery.”
Title: mRNA based in vivo MG1113 antibody production as a potential therapeutic approach for hemophilia
Authors: Miyoung Oh, Yujeong Jeong, Hyein Jung, Yongjoo Byeon, Heechun Kwak, Songseop Kim, Wonhyo Seo, Jaesung Jung, Hyukjin Lee
Find more posts on Hemostasis Today.
-
Mar 16, 2026, 14:52Gianluca Franceschini: The Difference in Breast Cancer is Made by the Team
-
Mar 16, 2026, 14:51Heghine Khachatryan: Hematologic Causes of Cryptogenic Stroke
-
Mar 16, 2026, 14:35Simon Senanu: Understanding the Extrinsic Coagulation Pathway
-
Mar 16, 2026, 14:27Mahesan Subramaniam: Why Messy Spaces Impact Women’s Stress Levels More Than Men’s
-
Mar 16, 2026, 14:21Marlies Alvarenga: Balancing the Scales in Women’s Cardiovascular Health
-
Mar 16, 2026, 13:32Filippo Cademartiri: Inflammation vs Cholesterol as Driver of Residual ASCVD Risk
-
Mar 16, 2026, 13:12Mariia Kumskova։ New Insights Into Platelet Dysfunction in Ehlers-Danlos Syndrome
-
Mar 15, 2026, 15:55Rare Diseases, Plasma-Derived Medicines and the Elephant in the Room – Part 2
-
Mar 15, 2026, 14:09Abdul Mannan: A Red Eye, a Blood Clot, and Ibrutinib – The Clinical Tightrope